تخطي إلى المحتوى

Evaxion und nicht offengelegter Kooperationspartner veröffentlichen vielversprechende Ergebnisse für EVX-B1-Impfstoff-Antigene gegen Staphylococcus aureus-Infektionen

KOPENHAGEN, Dänemark, April 08, 2024 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein Biotechnologie-Unternehmen in der klinischen Phase, das sich auf die Entwicklung von AI-Immunology™-gestützten Impfstoffen spezialisiert hat, freut sich, den erfolgreichen Abschluss mehrerer umfangreicher Infektionsstudien an Nicht-Nagetieren bekannt zu geben, in deren Rahmen die Antigene des präklinischen Impfstoffkandidaten EVX-B1 von Evaxion gegen Staphylococcus aureus (S. aureus) getestet wurden. In den Tierstudien führten die EVX-B1-Antigene zu einer deutlichen Verringerung der Krankheitslast. Gegenwärtig führen die beiden Unternehmen Gespräche über das weitere Vorgehen. Evaxion und nicht offengelegter Kooperationspartner veröffentlichen vielversprechende Ergebnisse für EVX-B1-Impfstoff-Antigene gegen Staphylococcus aureus-Infektionen

تقدم ميديجين لمحة إيجابية عن سلامة خلايا TCR-T المزودة ببروتين تبديل تحفيزي مشترك في الاجتماع السنوي لجمعية أبحاث السرطان الأمريكية 2024

Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents superior recombinant T cell receptor (rTCR) engineered T cell functionality as well as a favorable safety profile when rTCR-T cells are armored and enhanced with the PD1-41BB costimulatory switch protein (CSP) at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, USA. Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024

الباحثون يقتلون خلايا أورام المخ بالبلازما

Wissenschaftlern und Medizinern der Westsächsischen Hochschule Zwickau (WHZ), des Heinrich-Braun-Klinikums Zwickau (HBK) und des Universitätsklinikums Magdeburg ist es gelungen, Hirntumorzellen durch die Behandlung mit physikalischem Plasma abzutöten. Durch das Verfahren soll es möglich werden, Hirnhauttumore restlos zu entfernen. Hirntumore stellen sowohl Patienten als auch die behandelnden Ärzte vor große Herausforderungen. Durch ihr verdrängendes oder invasives Wachstum können sie erhebliche neurologische Beschwerden nach sich ziehen und unter Umständen auch das Leben bedrohen. Die komplette Entfernung eines Hirntumors ist leider nicht immer, ohne die Gesundheit des Patienten zu gefährden, möglich. Verbliebene Tumorreste erhöhen aber die Wahrscheinlichkeit eines erneuten Tumorwachstums. Genau an diesem Punkt setzen Prof. Dr. Maik Fröhlich von der Westsächsischen Hochschule Zwickau (WHZ) und die Mediziner PD Dr. Michael Luchtmann und Dirar Aldabek vom Heinrich-Braun-Klinikum Zwickau (HBK) sowie Prof. Dr. Christian Mawrin und Peter John vom Institut für Neuropathologie des Universitätsklinikums… 

more »Forscher töten Hirntumorzellen mit Plasma ab

دواء الحمض النووي الريبوزي المرسال يخفض الدهون في الدم

وفقًا لدراسة مضبوطة بالغُفْل ومزدوجة التعمية بقيادة باحثين من مستشفى بريغهام والنساء، وهو عضو مؤسس في نظام الرعاية الصحية ماس جينرال بريغهام، قد يخفض علاج تجريبي مستويات الدهون الثلاثية في الدم بشكل أكبر. تم تقديم النتائج في الدورة العلمية السنوية والمعرض للكلية الأمريكية لأمراض القلب 2024 ونُشرت في نفس الوقت في مجلة نيو إنجلاند الطبية. في الدراسة، تم توزيع 154 بالغًا يتلقون علاجًا مخفضًا للدهون مع ارتفاع متوسط أو شديد في الدهون الثلاثية بشكل عشوائي لتلقي إما 50 ملغ من أوليزارسن، أو 80 ملغ من أوليزارسن، أو دواء وهمي. أوليزارسن هو أولينوكليوتيد مضاد للاتجاه يثبط APOC3، وهو جين مرتبط بارتفاع مستويات الدهون الثلاثية عن طريق استهداف mRNA الخاص به. تم إعطاء الدواء تحت الجلد كل أربعة أسابيع على مدار عام واحد. مقارنةً بالدواء الوهمي، خفض أوليزارسن مستويات الدهون الثلاثية بنسبة 49% عند جرعة 50 ملغ و...

مزيد » دواء mRNA يهدف إلى خفض الدهون في الدم

فحص سرطان البروستاتا باستخدام PSA، ولوحة الكاليكرين، والتصوير بالرنين المغناطيسي

In this preliminary descriptive report from an ongoing randomized clinical trial, one additional high-grade cancer per 196 men and one low-grade cancer per 909 men were detected among those randomized to be invited to undergo a single prostate cancer screening intervention compared with those not invited to undergo screening. These preliminary findings from a single round of screening should be interpreted cautiously, pending results of the study’s primary mortality outcome. Authors: Anssi Auvinen, M.D., Ph.D., of Tampere University in Tampere, Finland, is the corresponding author. https://jamanetwork.com/journals/jama/fullarticle/2817323?guestAccessKey=0ec76eb2-a05b-4ae3-b31c-7a662e979189&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=040624

لقاح فموي للتهاب المسالك البولية هو بديل محتمل للمضادات الحيوية

Recurrent Urinary Tract Infections (UTIs) can be prevented for up to nine years in more than half of people given an oral spray-based vaccine and is a potential alternative to antibiotic treatments, finds research. Initial results from the first long-term follow-up study of the safety and effectiveness of the MV140 vaccine for recurrent UTIs are presented this weekend at the European Association of Urology (EAU) Congress in Paris. They show that in both men and women with recurrent UTIs, 54% of study participants remained UTI-free for nine years after the vaccine, with no notable side effects reported. Full results of the study are expected to be published by the end of 2024.

EHRA 2024:  New evidence links passive smoking with dangerous heart rhythm disorder

Exposure to secondhand smoke – even at small amounts – is linked with greater risk of a serious heart rhythm disorder, according to research presented at EHRA 2024, a scientific congress of the European Society of Cardiology (ESC). The likelihood of atrial fibrillation increased as the duration of passive smoking lengthened. “The dangers of secondhand smoke were significant regardless of whether individuals were at home, outdoors, or at work, indicating that exposure universally elevates the risk of atrial fibrillation,” said study author Dr. Kyung-Yeon Lee of Seoul National University Hospital, Seoul, Republic of Korea. “We should all make every effort to avoid spending time in smoky environments. The findings should also drive policymakers to further curb smoking in public areas and support smoking cessation programmes to improve public health.” https://esc365.escardio.org/EHRA-Congress/sessions/10100

Experimental drug could further reduce lipids in the blood in high-risk patients

An experimental treatment could further lower triglycerides in the blood, according to a placebo-controlled and double-blind trial led by researchers at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system. Results were presented at the 2024 American College of Cardiology’s Annual Scientific Session & Expo and simultaneously published in the New England Journal of Medicine. The trial randomized 154 adults on lipid-lowering therapy with moderate or severe hypertriglyceridemia to receive either 50mg olezarsen, 80mg olezarsen or placebo. Olezarsen is an antisense oligonucleotide that inhibits APOC3, a gene associated with higher levels of triglycerides, by targeting its mRNA. The subcutaneous medication was administered every four weeks, for a period of a year. Olezarsen reduced triglyceride levels by 49% at the 50mg dose and 53% at the 80mg dose, compared with placebo. The experimental drug also reduced… 

more »Experimental drug could further reduce lipids in the blood in high-risk patients


تقدم Antengene أربعة ملصقات ما قبل سريرية في مؤتمر AACR 2024

Antengene announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States. The posters showcased four of Antengene’s high-potential emerging programs, including ATG-042, tracking to a H1 2025 IND filing; ATG-022, in Phase II dose expansion studies in China and Australia; AnTenGagerTM platform, Antengene’s proprietary T-cell engager (TCE) platform; and ATG-102, which could be the first IND candidate from AnTenGagerTM platform.

تقدم Antengene أربعة ملصقات ما قبل سريرية في مؤتمر AACR 2024

Antengene announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States. The posters showcased four of Antengene’s high-potential emerging programs, including ATG-042, tracking to a H1 2025 IND filing; ATG-022, in Phase II dose expansion studies in China and Australia; AnTenGagerTM platform, Antengene’s proprietary T-cell engager (TCE) platform; and ATG-102, which could be the first IND candidate from AnTenGagerTM platform.